Search PubMed⌕ Search

Biomedical subjects

A Molavi

Publications and source records attributed to A Molavi.

At least 37 records · Page 2Linked to original sources

In-vitro and in-vivo comparison of mezlocillin and cefoxitin.

The efficacy, toxicity, microbiology and pharmacology of cefoxitin and mezlocillin were compared in a clinical and laboratory study. In 81 patients treated with cefoxitin and 83 treated with mezlocillin, clinical and bacteriological cures were achieved in 79.2% and 85.5% respectively. Both antibiotics were effective in the treatment of septicaemia, pulmonary infections, urinary tract infections, intra-abdominal and pelvic infections and skin and soft-tissue infections. Both were also effective in the treatment of anaerobic infections. No major haematological, hepatic, or renal toxicity was encountered in patients treated with either drug.

Adolescent↗

Clindamycin.

Explore the source record for details and available documents.

Bacteria↗

Metronidazole.

Explore the source record for details and available documents.

Absorption↗

Interactions between antibiotics and human neutrophils in the killing of staphylococci.

Normal and antibiotic-pretreated staphylococci were incubated with human neutrophils to determine the interactions between cells and antimicrobials in the killing of the organisms. Staphylococcus aureus 502A pretreated during log-phase growth with subinhibitory ((1/4) minimum inhibiting concentration) (MIC) concentrations of penicillin G were more susceptible to killing by normal neutrophils than untreated bacteria (intracellular survival 0.17+/-0.04 vs. 1.5+/-0.38%, mean+/-SEM, respectively, at 35 min in 14 experiments; P < 0.01 by t test). Furthermore, this enhanced susceptibility to killing was observed even when phagosome formation was inhibited by cytochalasin B (65.6+/-4.6% pencillintreated vs. 30.5+/-4.5% untreated killed at 30 min in 14 experiments, P < 0.001). Pretreatment of S. aureus with vancomycin similarly enhanced susceptibility to killing by cytochalasin B-treated polymorphonuclear leukocytes (PMN), whereas pretreatment with gentamicin did not. The enchancement of killing by pretreatment with cell wall-active antibiotics was present in a dose-response fashion to 1/16th the MIC. It required specific antimicrobial activity; i.e., penicillin activity was inhibited by penicillinase or by incubation with bacteria at 4 degrees C. It also required active cellular metabolism and intact neutrophils. For antibiotic-pretreated bacteria to be killed by normal and cytochalasin B-treated cells, phagocytosis or binding to the cells was essential via a serum opsonindependent mechanism. In experiments with the cytochalasin B-treated cells, all bound penicillin-treated bacteria were killed vs. only a fraction (70%) of the bound untreated bacteria. Penicillin in 10 times the MIC had no direct effects on PMN phagocytic, metabolic, or microbicidal functions against a nonsusceptible organism, Candida albicans. The results indicate a cooperative effect between cell wall-active antibiotics at low concentrations and human PMN in the killing of staphylococci. The model establishes conditions for the study of the mechanisms involved in the cooperation of these bactericidal systems.

Cytochalasin B↗

Metronidazole.

Explore the source record for details and available documents.

Administration, Oral↗

Perinephric abscess: an unusual presentation of perforation of the colon.

Perinephric abscess caused by spread of infection from an adjacent extrarenal focus is rare. Prior to diagnosis, several features of this case suggested such a pathogenesis: absence of an associated upper urinary tract infection or a distant focus for hematogenous seeding, and late recurrence of the abscess despite prompt clinical response following drainage and antimicrobial therapy. Specifically, the large bowel was suspected early on and subsequently documented as the source of infection because of the unusual finding of a polymicrobial perinephric abscess.

Abscess↗

In vitro susceptibility of atypical mycobacteria to rifampin.

Atypical mycobacteria (209 strains) were examined for susceptibility to rifampin by the proportion method by using Middlebrook 7H-10 agar. All strains of Mycobacterium kansasii and tap-water scotochromogens were inhibited by 0.25 to 1 mug of the drug per ml. Seventy-six per cent of M. scrofulaceum and 61% of M. intracellulare strains were susceptible to 4 mug/ml or less; 5% of the former and 8% of the latter were resistant to 16 mug/ml. All strains of M. gastri and M. triviale and most strains of M. terrae were sensitive to 1 to 4 mug/ml. Two strains of M. borstelense were both inhibited by 8 mug/ml. Nearly all strains of M. fortuitum were resistant to the drug. The results of this study suggest that rifampin may be a valuable agent for the treatment of many atypical mycobacterial infections.

Drug Resistance, Microbial↗

Herpes zoster.

Explore the source record for details and available documents.

England↗